Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature

BACKGROUND: Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global mediator. CASE PRESENTATIONS: We report a series of four patients, diagnosed w...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Johanna S., Tawa, Marianne, Chau, Nicole G., Kupper, Thomas S., LeBoeuf, Nicole R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356405/
https://www.ncbi.nlm.nih.gov/pubmed/28302100
http://dx.doi.org/10.1186/s12885-017-3194-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356405/
https://www.ncbi.nlm.nih.gov/pubmed/28302100
http://dx.doi.org/10.1186/s12885-017-3194-8

Ejemplares similares